nc318
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2018 (NCT03665285)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
Mechanism of action
- Sialic acid-binding Ig-like lectin 15Immunity, passive
SIGLEC15 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- nc318
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04699123 | Phase 2 | Feb 4, 2021 | Merck, National Cancer Institute (NCI), NextCure, Inc., Yale University |
| NCT04430933 | Phase 1/Phase 2 (Phase 2) | Jul 6, 2020 | NextCure, Inc. |
| NCT03665285 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2018 | NextCure, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NextCure, Inc. | For profit | 3 | 2 | 1 | 2018 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1